India, Aug. 11 -- Biohaven Ltd. (BHVN), a biopharmaceutical company, on Monday posted second quarter earnings, recording a narrower net loss due to decreased operating expenses.
The company is engaged in developing several drug discovery platforms, including the Kv7 ion channel modulation for epilepsy, MoDE and TRAP for extracellular protein modification in immunological diseases, and myostatin inhibition for neuromuscular and metabolic diseases.
Q2 Financial Results:
The second quarter net loss came to $137.31 million or $0.91 per share, considerably higher than the $198.15 million or $1.94 per share from a year ago.
While operating losses were $124.89 million this year, the same was recorded as $211.70 million in the same period of 20...